Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12029-009-9060-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of Nemolizumab in Patients With Prurigo Nodularis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Cureus
February 2025
Cardiology, Pakistan Navy Station (PNS) Shifa, Karachi, PAK.
This meta-analysis evaluated the efficacy and safety of nemolizumab in treating prurigo nodularis through a systematic review of randomized controlled trials. A comprehensive literature search was conducted across multiple databases, including PubMed, Embase, Cochrane Library, and Web of Science, identifying relevant studies until January 5th 2025. Four randomized controlled trials involving 859 participants were included in the final analysis.
View Article and Find Full Text PDFLaser ablation of a fourth ventricular hamartoma causing medically refractory hemifacial spasms in a child: illustrative case.
J Neurosurg Case Lessons
March 2025
Division of Pediatric Neurosurgery, Department of Neurosurgery, University of Utah, Primary Children's Hospital, Salt Lake City, Utah.
Background: Hamartomas of the floor of the fourth ventricle (HFFVs) are rare lesions that cause a variety of symptoms, including hemifacial spasm (HFS). When symptomatic, these deep-seated lesions are traditionally treated via open surgical approaches. The authors describe successful laser interstitial thermal therapy (LITT) of an HFFV causing intractable HFS.
View Article and Find Full Text PDFDenosumab for osteoporosis treatment: when, how, for whom, and for how long. A pragmatical approach.
Aging Clin Exp Res
March 2025
Interdisciplinary Center of Bone Diseases, Rheumatology Unit, Bone and Joint Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Denosumab produces a continuous increase in bone mineral density over ten years, associated with a low risk of vertebral and non-vertebral fractures. Denosumab is well tolerated and easy to manage in daily clinical practice. For all these reasons, this treatment has a huge success.
View Article and Find Full Text PDFThe efficacy of the 4-hook needle localization for pulmonary ground glass nodules: a single-center retrospective analysis.
J Cardiothorac Surg
March 2025
Department of Cardiothoracic Surgery, The Third Affiliated Hospital of Sun Yat-Sen University, No.600 Tianhe Road, Guangzhou, 510630, People's Republic of China.
Introduction: The aim of this study was to evaluate the efficacy of the 4-hook needle localization for pulmonary ground glass nodules (GGNs).
Methods: From November 1, 2021, to May 31, 2024, 194 patients were diagnosed with one or more GGNs by computed tomography (CT) scan and underwent preoperative CT-guided 4-hook needle localization followed by video-assisted thoracoscope surgery (VATS) wedge resection, segmentectomy or lobectomy. There were 226 nodules in all patients.
AWT020: a novel fusion protein harnessing PD-1 blockade and selective IL-2 Cis-activation for enhanced anti-tumor immunity and diminished toxicity.
Front Immunol
March 2025
Anwita Biosciences, San Carlos, CA, United States.
Background: The clinical success of the immune checkpoint inhibitor (ICI) targeting programmed cell death protein 1 (PD-1) has revolutionized cancer treatment. However, the full potential of PD-1 blockade therapy remains unrealized, as response rates are still low across many cancer types. Interleukin-2 (IL-2)-based immunotherapies hold promise, as they can stimulate robust T cell expansion and enhance effector function - activities that could synergize potently with PD-1 blockade.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!